Tempus, Median Technologies Collaborate on AI-Powered Lung Cancer Screening

Tempus AI Inc. is partnering with Median Technologies to incorporate the latter’s proprietary eyonis LCS into the Tempus Pixel platform. The pairing empowers clinical workflows with a tool to support informed diagnostic and disease management decisions.

An American Cancer Society study estimates that 20% of eligible U.S. individuals were screened for lung cancer in 2024. Closing the gap and achieving full participation among eligible individuals could prevent an estimated 62,110 lung cancer deaths over five years. eyonis LCS is an artificial intelligence (AI)-based CADe/CADx software as a medical device (SaMD) for lung cancer screening that enables clinicians to detect, characterize, and risk-stratify lung nodules from the same computed tomography (CT) image without additional workflow ssteps. eyonis LCS received U.S. Food and Drug Administration (FDA) 510(k) clearance in February.

“Activating our distribution collaboration with Tempus AI is a decisive step in bringing eyonis LCS to patients at national scale,” Median Technologies Founder/CEO Fredrik Brag said. “Tempus’ leadership in AI-enabled precision medicine, deeply integrated data-technology ecosystem, and market presence make them an exceptional partner to drive rapid and high-impact adoption of eyonis LCS across the United States.”

Through this collaboration, Tempus will integrate eyonis LCS into Tempus Pixel,¹ an FDA-cleared, CE-marked AI-enabled solution that provides advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. The integration of eyonis LCS will enable non-invasive characterization of CT-identified lung nodules at the time of nodule detection with its proprietary nodule malignancy score, a feature that will allow clinical teams to stratify and prioritize patients in lung cancer screening programs.

“We believe AI reaches its full potential when it helps clinicians identify disease earlier and more accurately,” stated Razik Yousfi, Tempus senior vice president and general manager, AI Products. “By expanding our Pixel platform with sophisticated lung cancer screening AI tools, we are enabling radiologists to manage complex caseloads while prioritizing early-stage detection. Our collaboration with Median Technologies is about more than technology; it’s about improving the standard of care and preventing avoidable deaths through better screening access.”

Tempus has expanded its diagnostic capabilities by developing and deploying advanced algorithms across radiology and pathology, helping clinicians deliver more precise, personalized care. In 2022, Tempus acquired Arterys, incorporating its AI-driven imaging tools—ranging from lung CTs and chest X-rays to cardiac MRIs—into the Tempus ecosystem. Tempus followed up that deal by purchasing Paige, which contributed a proprietary dataset of nearly 7 million clinically annotated, de-identified pathology slides.

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians for delivering personalized patient care and in parallel, facilitates the discovery, development, and delivery of optimal therapeutics.

Reference
¹ Tempus Pixel is manufactured and registered under Arterys Inc., a wholly owned subsidiary of Tempus, for both FDA and CE Mark purposes.